心脉医疗(688016) - 2020 Q1 - 季度财报

Financial Performance - Revenue for the first quarter was ¥99,193,139.59, up 7.68% compared to ¥92,115,606.08 in the previous year[11] - Net profit attributable to shareholders was ¥59,479,274.72, a significant increase of 32.42% from ¥44,915,773.52 in the prior year[11] - Total operating revenue for Q1 2020 was RMB 99,193,139.59, an increase of 7.3% from RMB 92,115,606.08 in Q1 2019[42] - Operating profit for Q1 2020 reached RMB 69,473,073.96, compared to RMB 52,510,433.74 in Q1 2019, reflecting a growth of 32.2%[42] - Net profit for Q1 2020 was RMB 59,479,274.72, an increase of 32.5% from RMB 44,915,773.52 in Q1 2019[45] - Total comprehensive income for Q1 2020 was approximately CNY 60.59 million, up from CNY 45.05 million in Q1 2019, representing a growth of 34.4%[50] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,225,196,911.43, an increase of 6.01% compared to the end of the previous year[11] - The company's cash and cash equivalents rose to RMB 947,893,977.82 as of March 31, 2020, compared to RMB 889,205,503.79 at the end of 2019, indicating a growth of approximately 6.54%[28] - The accounts receivable increased to RMB 40,066,118.39 from RMB 34,229,536.28, marking an increase of about 16.67%[28] - The company's total liabilities increased to CNY 99.70 million from CNY 89.74 million, reflecting a rise of about 11.5%[36] - The company's current liabilities totaled CNY 78.44 million, an increase from CNY 69.75 million, representing a growth of approximately 12.4%[36] - The total liabilities and equity amounted to CNY 1,228.54 million, an increase from CNY 1,157.95 million, indicating a growth of approximately 6.09%[39] Cash Flow - Operating cash flow for the period was ¥56,536,247.50, representing a 22.28% increase from the same period last year[11] - Cash inflow from operating activities in Q1 2020 was CNY 114.16 million, compared to CNY 97.25 million in Q1 2019, an increase of 17.4%[53] - Net cash flow from operating activities for Q1 2020 was CNY 56.54 million, up from CNY 46.24 million in Q1 2019, reflecting a growth of 22.3%[53] - The company reported a net increase in cash and cash equivalents of CNY 58.63 million for Q1 2020, compared to CNY 42.64 million in Q1 2019, indicating a growth of 37.5%[55] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,844[15] - Basic and diluted earnings per share remained stable at ¥0.83[11] - The basic and diluted earnings per share for Q1 2020 were both RMB 0.83, unchanged from Q1 2019[45] Research and Development - The proportion of R&D investment to operating income was 9.72%, a slight decrease of 0.1 percentage points from the previous year[11] - Research and development expenses for Q1 2020 amounted to RMB 8,653,733.43, up from RMB 6,922,008.40 in Q1 2019, indicating a focus on innovation[42] Government Support - Government subsidies recognized in the current period amounted to ¥6,759,718.14[11] - Other income surged by 2609.71% to RMB 6,759,718.14 in Q1 2020, compared to RMB 249,462.53 in Q1 2019, primarily due to increased government subsidies[22]